Immunosuppressive and antifibrotic therapy of systemic sclerosis

Expert Review of Dermatology

Volumn 2, Issue 2, 2007, Pages 203-215

  Olski, Thorsten M ^a   Hunzelmann, Nicolas ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

corticosteroids; cyclophosphamide; scleroderma; skin fibrosis

Indexed keywords

EID: 62849093119     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/17469872.2.2.203     Document Type: Article

References (94)

1. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am. J. Med. 118 (1), 2–10 (2005).
2. Mayes MD. Scleroderma epidemiology. Rheum. Dis. Clin. North Am. 29 (2), 239–254 (2003).
3. Mayes MD, Lacey JV Jr, Beebe-Dimmer J et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 48 (8), 2246–2255 (2003).
4. Tamaki T, Mori S, Takehara K. Epidemiological study of patients with systemic sclerosis in Tokyo. Arch. Dermatol. Res. 283 (6), 366–371 (1991).
5. Geirsson AJ, Steinsson K, Guthmundsson S, Sigurthsson V. Systemic sclerosis in Iceland. A nationwide epidemiological study. Ann. Rheum. Dis. 53 (8), 502–505 (1994).
6. Denton CP, Black CM. Scleroderma – clinical and pathological advances. Best Pract. Res. Clin. Rheumatol. 18 (3), 271–290 (2004).
7. Tashkin DP, Elashoff R, Clements PJ et al. Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. 354 (25), 2655–2666 (2006).
8. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 23 (5), 581–590 (1980).
9. Poormoghim H, Lucas M, Fertig N, Medsger TA Jr. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum. 43 (2), 444–451 (2000).
10. Bryan C, Knight C, Black CM, Silman AJ. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum. 42 (12), 2660–2665 (1999).
11. Charles C, Clements P, Furst DE. Systemic sclerosis:hypothesis driven strategies. Lancet 367, 1683–1691 (2006).
12. Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M. Increased expression of TGF-β receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-β signaling to scleroderma phenotype. J. Invest. Dermatol. 110 (1), 47–51 (1998).
13. Denton CP, Abraham DJ. Transgenic analysis of scleroderma: understanding key pathogenic events in vivo. Autoimmun. Rev. 3 (4), 285–293. (2004).
14. Horstmeyer A, Licht C, Scherr G, Eckes B, Krieg T. Signalling and regulation of collagen I synthesis by ET-1 and TGF-β1. FEBS J. 272 (24), 6297–6309 (2005).
15. Simms RW, Korn JH. Cytokine directed therapy in scleroderma: rationale, current status, and the future. Curr. Opin. Rheumatol. 14 (6), 717–722 (2002).
16. Hunzelmann N, Risteli J, Risteli L et al. Circulating type I collagen degradation products: a new serum marker for clinical severity in patients with scleroderma? Br. J. Dermatol. 139 (6), 1020–1025 (1998).
17. van der Slot AJ, Zuurmond AM, Bardoel AF et al. Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J. Biol. Chem. 278 (42), 40967–40972 (2003).
18. Smits P, Hofman H, Rosmalen F, Wollersheim H, Thien T. Endothelin-1 in patients with Raynaud’s phenomenon. Lancet 337 (8735), 236 (1991).
19. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346 (12), 896–903 (2002).
20. Korn JH, Mayes M, Matucci Cerinic M et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 50 (12), 3985–3993 (2004).
21. Brinckmann J, Kim S, Wu J et al. Interleukin 4 and prolonged hypoxia induce a higher gene expression of lysyl hydroxylase 2 and an altered cross-link pattern: important pathogenetic steps in early and late stage of systemic scleroderma? Matrix Biol. 24 (7), 459–468 (2005).
22. Valentini G. The assessment of the patient with systemic sclerosis. Autoimmun. Rev. 2 (6), 370–376 (2003).
23. Rodnan GP, Lipinski E, Luksick J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum. 22 (2), 130–140 (1979).
24. Black CM. Measurement of skin involvement in scleroderma. J. Rheumatol. 22 (7), 1217–1219 (1995).
25. Seibold JR. Clinical trials: types, design, and end-points. Curr. Opin. Rheumatol. 13 (6), 512–515 (2001).
26. Clements PJ. Measuring disease activity and severity in scleroderma. Curr. Opin. Rheumatol. 7 (6), 517–521 (1995).
27. Fisher MR, Mathai SC, Champion HC et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum. 54 (9), 3043–3050 (2006).
28. Schulze-Lohoff E, Seiberlich B, Hunzelmann N, Krieg T, Weber M. Intermediate molecular weight proteinuria identifies scleroderma patients with increased morbidity. J. Am. Soc. Nephrol. 17, 184A (2006).
29. Valentini G, Della Rossa A, Bombardieri S et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann. Rheum. Dis. 60 (6), 592–598 (2001).
30. Steen VD, Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum. 44 (12), 2828–2835 (1995).
31. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 43 (11), 2437–2444 (2000).
32. Steen VD, Medsger TA Jr. Case–control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 41 (9), 1613–1619 (1998).
33. Sharada B, Kumar A, Kakker R et al. Intravenous dexamethasone pulse therapy in diffuse systemic sclerosis. A randomized placebo-controlled study. Rheumatol. Int. 14 (3), 91–94 (1994).
34. Takehara K. Treatment of early diffuse cutaneous systemic sclerosis patients in Japan by low-dose corticosteroids for skin involvement. Clin. Exp. Rheumatol. 22 (3 Suppl. 33), S87 –S89 (2004).
35. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann. Intern. Med. 132 (12), 947–954 (2000).
36. Airo P, Danieli E, Parrinello G et al. Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results. Clin. Exp. Rheumatol. 22 (5), 573–578 (2004).
37. Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J. Rheumatol. 29 (2), 298–304 (2002).
38. Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J. Rheumatol. 29 (11), 2371–2378 (2002).
39. Calguneri M, Apras S, Ozbalkan Z et al. The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. Clin. Rheumatol. 22 (4–5), 289–294 (2003).
40. Valentini G, Paone C, La Montagna G et al. Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease. Scand. J. Rheumatol. 35 (1), 35–38 (2006).
41. Tyndall A, Saccardi R. Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: results from Phase I/II studies, prospective randomized trials and future directions. Clin. Exp. Immunol. 141 (1), 1–9 (2005).
42. Maas D, Schramm A, Jackle B, Raif W, Schubothe H. [Progressive systemic sclerosis – long-term treatment with azathioprin(author’s transl.)] Immun. Infekt. 7 (5), 165–169 (1979).
43. Nadashkevich O, Davis P, Fritzler M, Kovalenko W. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin. Rheumatol. 25 (2), 205–212 (2006).
44. van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J. Rheumatol. 35 (4), 364–372 (1996).
45. Pope JE, Bellamy N, Seibold JR et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 44 (6), 1351–1358 (2001).
46. Stratton RJ, Wilson H, Black CM. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxf.) 40 (1), 84–88 (2001).
47. Nihtyanova SI, Brough GM, Black CM, Denton CP. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis – a retrospective analysis. Rheumatology (Oxf.) 46 (3), 442–445 (2007).
48. Gisslinger H, Burghuber OC, Stacher G et al. Efficacy of cyclosporin A in systemic sclerosis. Clin. Exp. Rheumatol. 9 (4), 383–390 (1991).
49. Appelboom T, Itzkowitch D. Cyclosporine in successful control of rapidly progressive scleroderma. Am. J. Med. 82 (4), 866–867 (1987).
50. Denton CP, Sweny P, Abdulla A et al. Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases. Br. J. Rheumatol. 33 (1), 90–92 (1994).
51. Casoli P, Carretti C, Tumiati B. Scleroderma renal crisis as a possible complication of cyclosporin A withdrawal. Clin. Rheumatol. 13 (1), 126–128 (1994).
52. Clements PJ, Lachenbruch PA, Sterz M et al. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum. 36 (1), 75–83 (1993).
53. Jimenez SA, Sigal SH. A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine J. Rheumatol. 18 (10), 1496–1503 (1991).
54. Clements PJ, Seibold JR, Furst DE et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. Semin. Arthritis Rheum. 33 (4), 249–263 (2004).
55. Steen VD. Treatment of systemic sclerosis. Am. J. Clin. Dermatol. 2 (5), 315–325 (2001).
56. Goronzy JJ, Weyand CM. Long-term immunomodulatory effects of T lymphocyte depletion in patients with systemic sclerosis. Arthritis Rheum. 33 (4), 511–519 (1990).
57. Tarkowski A, Lindgren I. Beneficial effects of antithymocyte globulin in severe cases of progressive systemic sclerosis. Transplant. Proc. 26 (6), 3197–3199 (1994).
58. Matteson EL, Shbeeb MI, McCarthy TG et al. Pilot study of antithymocyte globulin in systemic sclerosis. Arthritis Rheum. 39 (7), 1132–1137 (1996).
59. Farge D, Passweg J, van Laar JM et al. EBMT/EULAR Registry. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann. Rheum. Dis. 63 (8), 974–981 (2004).
60. McSweeney PA, Nash RA, Sullivan KM et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 100 (5), 1602–1610 (2002).
61. Quan T, He T, Kang S, Voorhees JJ, Fisher GJ. Connective tissue growth factor: expression in human skin in vivo and inhibition by ultraviolet irradiation. J. Invest. Dermatol. 118 (3), 402–408 (2002).
62. Yin L, Yamauchi R, Tsuji T, Krutmann J, Morita A. The expression of matrix metalloproteinase-1 mRNA induced by ultraviolet A1 (340–400 nm) is phototherapy relevant to the glutathione (GSH) content in skin fibroblasts of systemic sclerosis. J. Dermatol. 30 (3), 173–180 (2003).
63. Herrmann G, Brenneisen P, Wlaschek M et al. Psoralen photoactivation promotes morphological and functional changes in fibroblasts in vitro reminiscent of cellular senescence. J. Cell. Sci. 111 (Pt 6), 759–767 (1998).
64. Breuckmann F, Gambichler T, Altmeyer P, Kreuter A. UVA/UVA1 phototherapy and PUVA photochemotherapy in connective tissue diseases and related disorders: a research based review. BMC Dermatol. 4 (1), 11 (2004).
65. von Kobyletzki G, Uhle A, Pieck C, Hoffmann K, Altmeyer P. Acrosclerosis in patients with systemic sclerosis responds to low-dose UV-A1 phototherapy. Arch. Dermatol. 136 (2), 275–276 (2000).
66. Greinix HT, Volc-Platzer B, Rabitsch W et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 92 (9), 3098–3104 (1998).
67. Rook AH, Freundlich B, Jegasothy BV et al. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. Arch. Dermatol. 128 (3), 337–346 (1992).
68. Knobler RM, French LE, Kim Y et al. Systemic Sclerosis Study Group. A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis. J. Am. Acad. Dermatol. 54 (5), 793–799 (2006).
69. Riemekasten G, Jepsen H, Burmester GR, Hiepe F. [Iloprost administration over 21 days as an effective therapy in systemic scleroderma – case report and review of the literature]. Z. Rheumatol. 57 (2), 118–124 (1998).
70. Stratton R, Shiwen X, Martini G et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J. Clin. Invest. 108 (2), 241–250 (2001).
71. McKown KM, Carbone LD, Bustillo J, Seyer JM, Kang AH, Postlethwaite AE. Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen. Arthritis Rheum. 43 (5), 1054–1061 (2000).
72. Ellman MH, McDonald PA, Hayes FA. Etanercept as treatment for diffuse scleroderma: a pilot study. Arthritis Rheum. 43 (Suppl.), s392 (2000) (Abstract).
73. Vlachoyiannopoulos PG, Tsifetaki N, Dimitriou I, Galaris D, Papiris SA, Moutsopoulos HM. Safety and efficacy of recombinant γ interferon in the treatment of systemic sclerosis. Ann. Rheum. Dis. 55 (10), 761–768 (1996).
74. Hunzelmann N, Anders S, Fierlbeck G et al. Systemic scleroderma. Multicenter trial of 1 year of treatment with recombinant interferon γ. Arch. Dermatol. 133 (5), 609–613 (1997).
75. Stevens W, Vancheeswaran R, Black CM. α interferon-2a (Roferon-A) in the treatment of diffuse cutaneous systemic sclerosis: a pilot study. UK Systemic Sclerosis Study Group. Br. J. Rheumatol. 31 (10), 683–689 (1992).
76. Black CM, Silman AJ, Herrick AI et al. Interferon-α does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 42 (2), 299–305 (1999).
77. Giordano N, Papakostas P, Lucani B et al. Serum relaxin in systemic sclerosis. J. Rheumatol. 32 (11), 2164–2166 (2005).
78. Jones R. Relaxin (Connetics/Celltech). Drugs 4 (2), 206–217 (2001).
79. McCormick LL, Zhang Y, Tootell E, Gilliam AC. Anti-TGF-β treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J. Immunol. 163 (10), 5693–5699 (1999).
80. Denton CP, Merkel PA, Furst DE et al. Cat-192 Study Group; Scleroderma Clinical Trials Consortium. Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled Phase I/II trial of CAT-192. Arthritis Rheum. 56 (1), 323–333 (2007).
81. Santiago B, Gutierrez-Canas I, Dotor J et al. Topical application of a peptide inhibitor of transforming growth factor-β1 ameliorates bleomycin-induced skin fibrosis. J. Invest. Dermatol. 125 (3), 450–455 (2005).
82. Louneva N, Saitta B, Herrick DJ, Jimenez SA. Transcriptional inhibition of type I collagen gene expression in scleroderma fibroblasts by the antineoplastic drug ecteinascidin 743. J. Biol. Chem. 278 (41), 40400–40407 (2003).
83. Giacomelli R, Valentini G, Salsano F et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J. Rheumatol. 29 (4), 731–736 (2002).
84. Enomoto DN, Mekkes JR, Bossuyt PM et al. Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis). J. Am. Acad. Dermatol. 41 (6), 915–922 (1999).
85. Guillevin L, Amoura Z, Merviel P et al. Treatment of progressive systemic sclerosis by plasma exchange: long-term results in 40 patients. Int. J. Artif. Organs 13 (2), 125–129 (1990).
86. Polisson RP, Gilkeson GS, Pyun EH, Pisetsky DS, Smith EA, Simon LS. A multicenter trial of recombinant human interferon γ in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels. J. Rheumatol. 23 (4), 654–658 (1996).
87. Grassegger A, Schuler G, Hessenberger G et al. Interferon-γ in the treatment of systemic sclerosis: a randomized controlled multicentre trial. Br. J. Dermatol. 139 (4), 639–648 (1998).
88. Kahan A, Amor B, Menkes CJ, Strauch G. Recombinant interferon-γ in the treatment of systemic sclerosis. Am. J. Med. 87 (3), 273–277 (1989).
89. Freundlich B, Jimenez SA, Steen VD, Medsger TA Jr, Szkolnicki M, Jaffe HS. Treatment of systemic sclerosis with recombinant interferon-γ. A Phase I/II clinical trial. Arthritis Rheum. 35 (10), 1134–1142 (1992).
90. Seibold JR, Korn JH, Simms R et al. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 132 (11), 871–879 (2000).
91. Morton SJ, Powell RJ. Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma. Rheumatology (Oxf.) 39 (8), 865–869 (2000).
92. The EULAR Scleroderma Trials and Research Group www.eustar.org
93. Clinical trials website www.clinicaltrials.gov
94. Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial www.astis.org